Skip to NavigationSkip to content

Novartis champion advanced breast cancer survival data at ESMO 2021

Published on 22/09/21 at 11:00am

Novartis has presented captivating new data in advanced breast cancer, which championed the longest ever reported median overall survival, as well as quality of life for metastatic prostate cancer patients.

In the UK, breast cancer is the most common type of cancer and 30% of women with earlier stages of breast cancer will develop advanced disease.

The data from the final overall survival analysis of the Phase III MONALEESA-2 study showed that after five years, patients treated with ribociclib in combination with letrozole, in contrast to placebo plus letrozole, had more than a 50% chance of survival. The trial was conducted on postmenopausal women with hormone receptor-positive advanced or metastatic breast cancer with no prior systemic treatment for advanced disease.

EU approves breast cancer drug Enhertu | Pharmafile

New NICE recommendation for Astellas prostate cancer drug | Pharmafile

Mari Scheiffele, Novartis Oncology General Manager, UK & Ireland states, “The deeper analysis of the statistically significant overall survival data for Kisqali is promising. It not only demonstrates our bold patient-first approach and ongoing commitment to the breast cancer community, but continued alignment to the priorities for the NHS in its Long-Term Plan for cancer patients.”

The Phase III VISION study also showed delay in the worsening of health-related quality of life and pain in pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC) , who have been treated with radioligland therapy Lu-PSMA-617, compared to standard of care alone.

Alessandra Dorigo, General Manager UK, Ireland, Baltics and Nordics in Novartis Advanced Accelerator Applications (AAA) comments, “The data from the Phase III VISION study of a radioligand therapy in this advanced prostate cancer setting confirm the potential of Lu-PSMA-617 to support better quality of life outcomes for people living with mCRPC.”

Lina Adams


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches